CD69

Chr 12

CD69 molecule

Also known as: AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3

The CD69 protein is a transmembrane receptor that regulates immune cell homeostasis by controlling T-cell differentiation, promoting regulatory T-cell conversion, and modulating inflammatory responses in various immune cell types including T-lymphocytes, NK cells, and platelets. Based on current medical literature, pathogenic mutations in CD69 have not been definitively associated with recognized human genetic diseases. The gene shows tolerance to loss-of-function variants (pLI = 0.03, LOEUF = 0.92), suggesting that complete loss of CD69 function may not cause severe developmental disorders.

Summary from RefSeq, UniProt
Research Assistant →
8
Active trials
392
Pubs (1 yr)
0
P/LP submissions
P/LP missense
0.92
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryCD69
Population Constraint (gnomAD)
Low constraint (pLI 0.03) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.92LOEUF
pLI 0.030
Z-score 1.75
OE 0.40 (0.200.92)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
-0.26Z-score
OE missense 1.07 (0.921.25)
112 obs / 104.5 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.40 (0.200.92)
00.351.4
Missense OE1.07 (0.921.25)
00.61.4
Synonymous OE0.78
01.21.6
LoF obs/exp: 4 / 10.0Missense obs/exp: 112 / 104.5Syn Z: 1.05
DN
0.77top 25%
GOF
0.76top 25%
LOF
0.2092th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CD69 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Malignant Glioma of BrainAstrocytomaMalignant Astrocytoma

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

RECRUITING
NCT05686798Phase PHASE1Henry Ford Health SystemStarted 2022-11-29
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Hidradenitis Suppurativa

Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy

NOT YET RECRUITING
NCT05208099Lille Catholic UniversityStarted 2024-01-01
Blood testsexeresisabdominoplasty
Psoriasis VulgarisPsoriasisSkin Diseases

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

ACTIVE NOT RECRUITING
NCT05185258Phase PHASE4Aarhus University HospitalStarted 2022-02-16
EnstilarPlacebo-vehicle
Type1diabetes

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

RECRUITING
NCT05054361Institut National de la Santé Et de la Recherche Médicale, FranceStarted 2022-01-01
MAIT cells analysisMAIT cytokines production analysisLactulose/Mannitol Test
Meningiomas

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

ACTIVE NOT RECRUITING
NCT02648997Phase PHASE2Dana-Farber Cancer InstituteStarted 2016-03
Nivolumab - 240 mgIpilimumab - 1 mg/kgNivolumab - 480 mg
Rectal Cancer PatientsObesity &Amp; OverweightLocally Advanced Rectal Cancer (LARC)

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

NOT YET RECRUITING
NCT07314528Phase PHASE2St. James's Hospital, IrelandStarted 2026-04
GLP-1 receptor agonistTotal neoadjuvant therapy (TNT)
EndometriosisAdenomyosis

Pain in Endometriosis And the Relation to Lifestyle

RECRUITING
NCT06332560Phase NARadboud University Medical CenterStarted 2024-10-04
Anti-inflammatory diet (DI)Cognitive behavioral therapy (CBT)
COVID-19

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

ACTIVE NOT RECRUITING
NCT05515042Phase PHASE2The Aurum Institute NPCStarted 2022-07-25
Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Clinical Literature
Open Research Assistant →